Medical Patent News

RSS

USPTO issues new patent to PBL's RNAi technology

Plant Bioscience Limited (PBL) is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued out US Patent No. 8,097,710 with fundamental claims directed to methods of inducing gene silencing using short RNA molecules, or DNA constructs encoding short RNA molecules, in a wide range of organisms, including in plants and humans.

19 Jan 2012

Ampio announces two new European patents for Zertane combination therapy

Ampio Pharmaceuticals, Inc., today announced notification by the European Patent Office they will be awarded two new patents in Europe for the combination of Zertane with any erectile dysfunction drug of the PDE5 inhibitors family such as sildenafil, tadalafil and the likes and for a combination of Zertane with compounds that reduce the side effects of tramadol.

18 Jan 2012

USPTO issues patent to SANUWAVE's new method that produces acoustic shock waves

SANUWAVE Health, Inc. today announced that the U.S. Patent and Trademark Office (USPTO) has issued the Company patent number 8,092,401, titled "Method and Apparatus for Producing Shock Waves for Medical Applications."

18 Jan 2012

Alnylam sues Tekmira over LNP-formulated siRNA molecules

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has filed a patent infringement lawsuit against Tekmira Pharmaceuticals Corporation in the U.S. District Court of the District of Massachusetts.

18 Jan 2012

ISU receives U.S. patent for phytol-derived adjuvant

While conducting research on cancer, Swapan Ghosh and a team of graduate and doctoral students discovered a phytol-derived adjuvant. That adjuvant formula just became U.S. Patent No. 8,088,395.

13 Jan 2012

Amarantus receives U.S. patent titled, 'Dopaminergic Neuronal Survival-Promoting Factors and Uses Thereof'

Amarantus BioSciences, Inc., a biotechnology company developing MANF, a first-in-class disease-modifying therapeutic protein, today announced U.S. Patent Number 8,084,425 has been issued for MANF entitled, Dopaminergic Neuronal Survival-Promoting Factors and Uses Thereof.

12 Jan 2012

USPTO issues patent to Unigene's peptide-based therapeutics for obesity

Unigene Laboratories, Inc., a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that it had been granted U.S. Patent No. 8,076,291 from the United States Patent and Trademark Office.

11 Jan 2012

Saladax increases claims in immunoassay space to 15 patents

Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today that it has been issued six patents within the last 12 months, bringing the company's total to 15 issued U.S. patents, all of which contain broad claims in the immunoassay space.

11 Jan 2012

Oramed files provisional patent application with USPTO for combination diabetes therapy

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that it has filed a provisional patent application with the United States Patent and Trademark Office for a combination therapy of its lead compound, ORMD-0801 in combination with its oral exenatide formulation, ORMD-0901. There is no such approved combination product available on the market today.

11 Jan 2012

Third-party to prepare FDA submittals for NanoLogix

NanoLogix Inc., an innovator in the accelerated detection, identification and antibiotic sensitivity determination of live bacteria announces that has instructed a third-party to prepare a total of six applications for submittal to the US FDA.

11 Jan 2012

USPTO issues patent to Lixte's lead compounds for treatment of neurological diseases

Lixte Biotechnology Holdings announces that the United States Patent and Trademark Office awarded a patent for the use of lead compounds from each of two different types of drugs, protein phosphatase inhibitors and histone deacetylase inhibitors, for the potential prevention and treatment of neurodegenerative diseases.

9 Jan 2012

Mylan confirms Actoplus Met XR patent challenge

Mylan Inc. today confirmed that the company has been sued by Takeda Pharmaceutical Company, Watson Pharmaceuticals and Andrx Labs in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Pioglitazone Hydrochloride and Extended-release Metformin Hydrochloride tablets, 15 mg/1000 mg and 30 mg/1000 mg.

9 Jan 2012

New U.S. patent covers key element of Xencor's Xtend half-life prolongation technology

Xencor, Inc., a company using its proprietary Protein Design Automation (PDA) platform technology to engineer next-generation antibodies, announced today that the U.S. Patent and Trademark Office has issued Xencor a broad patent covering optimized monoclonal antibody variants and their application for extending in vivo half-life of antibodies.

7 Jan 2012

USPTO issues patent to Tris Pharma's OralXR+ platform

Tris Pharma, an emerging specialty pharmaceutical company, announced the US grant of its core technology patent for its OralXR+ platform. This is the first patent grant of a substantial estate filed by Tris Pharma and covers a multitude of actives having modified release formulations comprising drug-ion exchange resin complexes.

7 Jan 2012

Mazor Robotics receives European patent titled, 'Miniature Bone-mounted Surgical Robot'

Mazor Robotics Ltd., a developer of innovative surgical robots and complementary products, today announced that the European Patent Office granted European Patent No. 1414362 entitled "Miniature Bone-mounted Surgical Robot," which covers the Company's flagship product, Renaissance.

7 Jan 2012

SANUWAVE receives U.S. patent titled, 'Device for the Application of Acoustic Shock Waves'

SANUWAVE Health, Inc., an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, today announced that the U.S. Patent and Trademark Office (USPTO) has issued the Company patent number 8,088,073, titled "Device for the Application of Acoustic Shock Waves."

7 Jan 2012

UCSF appeals USPTO panel judgment in favor of InSite Vision

InSite Vision Incorporated today announced that the University of California, San Francisco (UCSF) has appealed the judgment of the United States Patent and Trademark Office (USPTO) panel that found in favor of the Company in its patent interference litigation with UCSF.

6 Jan 2012

Arcion receives U.S. patent allowance for ARC-2022 to treat PHN

Arcion Therapeutics, a clinical stage biotechnology company developing topical therapies for chronic pain, today announced that it received notice of allowance for a US Patent for its high strength gel formulation of topical lidocaine, ARC-2022.

5 Jan 2012

NovaSterilis awarded soft tissue processing patent

NovaSterilis Inc., specializing in developing applications for supercritical carbon dioxide, has been granted US Patent 8,034,288 B2. The patent, dated October 11, 2011 entitled “Method and Apparatus for Cleaning of Viable Donor Soft Tissue”, covers a new method for cleaning soft allograft tissue including tendon, fascia, and skin with a supercritical fluid, thus avoiding other harmful chemical solvents that may leave residual chemicals.

4 Jan 2012

J&J will not join Medicines Patent Pool; Company's pharma head says mechanism could 'cause disaster'

Pharmaceutical company "Johnson & Johnson has rejected calls to offer patent rights on its HIV medicines to generic drug companies through a" Medicines Patent Pool, created to promote low-cost antiretroviral drugs in low-income countries and the development of new drug combinations and formulations, the Financial Times reports.

4 Jan 2012